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Acetaminophen (N-acetyl-p-aminophenol, APAP),
also referred to as paracetamol, is widely used as an
analgesic and antipyretic drug throughout the
world.  In the United Kingdom, about 3.2 × 109 tab-
lets of APAP are consumed every year, which is
equivalent to an average of 55 tablets/person (Jones,
1998).  As an over-the-counter drug, it can be read-
ily obtained without prescription.  Although APAP
is generally harmless at therapeutic doses, overdose
causes hepatotoxicity (Davidson and Eastham, 1966;
Mitchell, 1988).  In addition, susceptibility to
APAP-induced hepatotoxicity is modified by vari-
ous factors such as alcohol abuse, fasting and concom-
itant drug use.  In Japan, APAP has usually been
consumed as combination tablets or granules and
rarely used alone except as a suppository.  However,
since recent reports that the use of salicylic acid in
combination cold remedies is associated with
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Acetaminophen (APAP), the most commonly sold over-the-counter antipyretic analgesic,
is generally considered harmless at therapeutic doses.  However, APAP overdose causes
severe and sometimes fatal hepatic damage in humans and experimental animals.  In the
United States and Europe, the incidence of liver injury due to APAP overdose, either with
suicidal intent or by accident, is increasing.  Recently, even in Japan, APAP has become
more commonly used alone, especially in children with a view to prevention of Reye's
syndrome.  Thus, understanding the hepatotoxicity induced by APAP overdose is very im-
portant.  To date, the mechanisms underlying APAP toxicity are considered to be associat-
ed with i) covalent binding to cellular macromolecules of a reactive intermediate metabolite
of APAP produced by cytochrome P450 (CYP), N-acetyl-p-benzoquinoneimine, and ii)
oxidative stress.  APAP-induced hepatotoxicity is modified by associated risk factors such
as alcohol abuse, fasting and concomitant drugs.  Even therapeutic doses of APAP sometimes
induce hepatic damage in the presence of these risk factors.  N-Acetylcysteine (NAC), one
of the cysteine prodrugs, is the most widely used for treating APAP-induced liver injury.
In addition to NAC, CYP2E1 inhibitors and antioxidants may also serve as mechanism-
based antidotes for APAP overdose.  Moreover, inducers of heat shock protein (HSP) (in
particular HSP25 and HSP70i) without any side effects might be new-type antidotes.
key words:  acetaminophen; N-acetyl-p-benzoquinoneimine; cytochrome P450 2E1; hepatotoxicity;
oxidative stress
18
I. Sumioka et al.
Reye’s syndrome in children with influenza or
varicella infection (Belay et al., 1999), APAP has
become more likely to be used alone in Japan and in
other countries.  Therefore, it is important that we
review APAP toxicity, even though APAP-induced
hepatic injury is not a newly emerging problem.
APAP-induced hepatotoxicity has been dem-
onstrated in experimental animals as well as clinical
cases.  Mice and hamsters have been shown to be
very sensitive to the hepatotoxic effects of APAP,
developing a fulminant centrilobular necrosis simi-
lar to that observed in humans (Mitchell et al.,
1973; Davis et al., 1974; Potter et al., 1974).  Rats,
rabbits and guinea pigs are, however, relatively
resistant to APAP insult (Boyd and Bereczky, 1966;
Madhu et al, 1992).
This review focuses on the mechanisms under-
lying APAP-induced hepatotoxicity, risk factors
that increase susceptibility to the hepatotoxic ef-
fects of APAP, and protection against the toxicity.
Mechanisms of APAP-Induced
Hepatotoxicity
Reactive intermediate metabolite of APAP
APAP is biotransformed and eliminated as nontoxic
glucuronic acid and sulfate conjugates.  Glucuro-
nide is provided by UDP-glucuronic acid, and sul-
fation is dependent on phosphoadenylsulfate
(Clements et al., 1984).  Furthermore, the mixed-
function oxidase system cytochrome P450 (CYP)
participates in metabolizing a small proportion of
APAP at therapeutic doses.  The metabolism of
APAP by CYP leads to the formation of N-acetyl-p-
benzoquinoneimine (NAPQI), a highly reactive in-
termediate metabolite (Dahlin et al., 1984), which is
normally detoxified by conjugation with reduced
glutathione (GSH).
After high doses of APAP, the capacity for its
removal by hepatic conjugation with glucuronide
and sulfate is exceeded, and more of the reactive
metabolite NAPQI is formed.  Consequently, more
NAPQI is conjugated with GSH, and when hepatic
GSH is depleted, more NAPQI will bind covalently
to cellular macromolecules (Jollow et al., 1973;
Potter and Hinson, 1986).  This is thought to lead to
a loss of protein thiol groups (Moore et al., 1985;
Kyle et al., 1990) and ultimately to cell death.  In
humans, CYP2E1, CYP1A2 and CYP3A4 have been
thought to contribute to the metabolism of APAP to
form NAPQI (Raucy et al., 1989; Patten et al., 1993;
Thummel et al., 1993; Nelson, 1995).  However,
recent pharmacokinetics studies in human volun-
teers have demonstrated that involvement of
CYP1A2 and CYP3A4 in NAPQI formation in vivo
is much less than that of CYP2E1, as omeprazole
(CYP1A2 inducer) and rifampicin (CYP3A4 induc-
er) treatment have no effect on the formation of
NAPQI from APAP, whereas disulfiram (CYP2E1
inhibitor) treatment decreases NAPQI formation
(Sarich et al., 1997; Manyike et al., 2000).  Studies
using CYP2E1 and CYP1A2 knockout mice have
shown that the former, but not the latter, are more
resistant to APAP-induced hepatotoxicity than
wild-type animals (Lee et al., 1996; Tonge et al.,
1998; Zaher et al., 1998), indicating that CYP2E1 is
a primary contributor to APAP biotransformation
among CYPs.  Concerning the other CYP enzymes
responsible for bioactivation of APAP, Hazai et al.
(2002) recently reported that selective inhibition of
CYP2A6 as well as CYP2E1 significantly decreas-
ed NAPQI formation in human liver microsomes,
whereas CYP1A2 and CYP3A4 inhibition did not
affect NAPQI production, suggesting that CYP2A6
may also be responsible for APAP bioactivation.
However, the role of CYP2A6 in APAP metabo-
lism in vivo remains to be established.  Overall, it is
feasible that the principal CYP responsible for
APAP toxicity is CYP2E1.
Oxidative stress
Oxidative stress is also considered to be involved in
the induction of hepatotoxicity by APAP.  The one-
electron oxidation of APAP by CYPs may generate
reactive oxygen species (ROS).  Hydrogen perox-
ide and superoxide are produced during metabolic
activation of APAP in the mixed function oxidase
system (Nordblom and Coon, 1977; Kuthan et al.,
1978; de Vries, 1981).  It has been reported that
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APAP overdose causes decreases in antioxidant
enzyme activities such as catalase and glutathione
peroxidase (Lores Arnaiz et al., 1995; Chen and
Lin, 1997), levels of endogenous antioxidants such
as α-tocopherol (α-Toc) and reduced forms of co-
enzyme Q9 (CoQ9H2) and coenzyme Q10 (CoQ10H2)
(Amimoto et al., 1995; Sumioka et al., 1998), and
the GSH/oxidized glutathione (GSSG) ratio
(Jaeschke, 1990; Lores Arnaiz et al., 1995; Amimoto
et al., 1995) in animal livers.  These endogenous
antioxidants, especially α-Toc, CoQ9H2 and
CoQ10H2 scavenge lipid peroxyl radicals and con-
sequently their own levels decrease (Matsura et al.,
1992a, 1992b).  Although there are arguments that
lipid peroxidation may be a consequence rather
than the cause of APAP-induced cell damage
(Mitchell et al., 1981, 1984), our time course data
obtained by quantitative analysis of biomarkers in
mice revealed that the reduction in hepatic CoQ9H2
and CoQ10H2 levels preceded increases in the thio-
barbituric acid-reactive substance (TBARS) con-
tent as an index of lipid peroxidation and plasma
alanine aminotransferase (ALT) activity following
APAP treatment (Amimoto et al, 1995).  Moreover,
pretreatment with oxidized coenzyme Q10 (CoQ10)
resulted in an increase in hepatic CoQ10H2 and a
marked reduction in hepatic TBARS content and
plasma ALT activity without affecting hepatic GSH
after APAP injection (Amimoto et al., 1995).
Pretreatment with α-Toc also suppressed the in-
crease in the hepatic TBARS content and plasma
ALT activity without affecting the hepatic GSH
level (Amimoto et al., 1995).  These results strongly
suggest that lipid peroxidation is involved in the
mechanism of APAP-induced hepatic injury.
Recently, it has been reported that the forma-
tion of reactive nitrogen species such as peroxy-
nitrite followed by extensive protein nitration is
also associated with APAP-induced hepatotoxicity
(Hinson et al., 1998; Knight et al., 2001).
Risk Factors
Even therapeutic doses of APAP sometimes induce
hepatotoxicity in the presence of risk factors (such
as alcohol abuse, fasting and drug interaction),
which increase susceptibility to the hepatotoxic
effects of APAP.
Alcohol
Interaction between alcohol and APAP has been
recognized since the late 1970s (McClain et al.,
1980).  However, the APAP-alcohol interaction is
very complicated, because acute and chronic alco-
hol intakes have opposite effects.  Chronic alcohol
intake increases hepatic CYP2E1 activity (Perrot et
al., 1989) and decreases the GSH level (Lauterburg
and Velez, 1988), especially the liver mitochondrial
GSH level (Hirano et al., 1992; Zhao et al., 2002;
Zhao and Slattery 2002).  These changes lead to an
increase in NAPQI formation and a decrease in
NAPQI detoxification, resulting in accumulation of
NAPQI.  Consequently, the severity of APAP-induced
hepatotoxicity is enhanced by chronic alcohol in-
take (Sato et al., 1981a; Zimmerman and Maddrey,
1995; Schmidt et al., 2002), and even a therapeutic
dose of APAP (generally considered to be nontoxic
in nonalcoholics) may lead to hepatotoxicity.  On
the other hand, acute alcohol intake reduces the
severity of APAP-induced hepatotoxicity (Rumack
et al., 1981; Banda and Quart 1982).  In rats, this
effect may be due to direct inhibition by alcohol of
the biotransformation of APAP to NAPQI (Sato et
al., 1981b, 1981c).  Because alcohol itself is metab-
olized not only by alcohol dehydrogenase but also
by CYP2E1 (microsomal ethanol oxidizing system;
MEOS) and MEOS plays a major role when blood
ethanol levels are high (Lieber, 1990), alcohol may
competitively inhibit biotransformation of APAP to
NAPQI.  In these studies, APAP was administered
when ethanol was still present in the blood circula-
tion.  Because ethanol is both a substrate and in-
hibitor of CYP2E1 (Lieber, 1997), the relative tim-
ing of APAP and ethanol ingestion is critical when
attempting to elucidate the effect of short-term
ethanol exposure on APAP metabolism.  Recently,
Thummel et al. (2000) reported, from studies in
healthy adult volunteers, that the increase in
NAPQI formation caused by ethanol occurred only
when APAP was given after ethanol had cleared
from the body.
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Fasting
Fasting has also been considered a risk factor for
APAP-induced hepatotoxicity.  Whitcomb and
Block (1994) reported a clinical study which found
that APAP-induced hepatotoxicity after an over-
dose is more likely to be associated with recent fast-
ing than recent alcohol use.  In rats, fasting causes
severe malnutrition, and the capacity of hepatic
conjugation of APAP with glucuronide and sulfate
decreases (Price et al., 1986, 1987).  Consequently,
more APAP is metabolized by CYPs, resulting in
more NAPQI production.  Although NAPQI is de-
toxified by conjugation with GSH, fasting also de-
creases hepatic GSH (Langley and Kelly, 1992; Vogt
and Richie, 1993).  Therefore, fasting may potentiate
APAP-induced hepatotoxicity.
Drug interactions
Finally, long-term treatment with drugs that induce
CYPs may increase the risk of APAP-induced liver
damage.  Carbamazepine, phenytoine, isoniazid
and troglitazone are considered to induce CYPs,
and therefore long-term use of these drugs enhances
APAP-induced hepatotoxicity (Smith et al., 1986;
Minton et al., 1988; Crippin, 1993; Li et al., 2002).  In
contrast, susceptibility to APAP liver injury is de-
creased by pretreatment with CYP inhibitors such
as piperonyl butoxide and 4-methylpyrazone (Brady
et al., 1991; Brennan et al., 1994; Kucukardali et al.,
2002, Hazai et al., 2002).
Protection against APAP-Induced
Hepatotoxicity
Cysteine prodrugs
GSH plays an important role in protecting the liver
against APAP-induced hepatotoxicity, because
NAPQI is detoxified by conjugation with GSH.
Therefore, stimulation of hepatic GSH synthesis is
feasible for prevention of APAP-induced hepatic
injury.  GSH, a tripeptide comprising glutamate,
cysteine and glycine, is synthesized by a two-step
reaction.  The first step is catalyzed by γ-glutamyl-
cysteine synthase to form γ-glutamylcysteine.  In
the second step, GSH synthase catalyzes the reac-
tion between glycine and γ-glutamylcysteine to
form GSH (Wang and Ballatori, 1998).  The first
step catalyzed by γ-glutamylcysteine synthase
Table 1.  Protective effect of cysteine prodrugs on APAP-induced hepatotoxicity
       Compound Experimental model References
Mouse hepatocytes Massey and Racz 1981
    (in vitro)
N-Acetylcysteine Rats (in vivo) Lauterburg et al. 1983
Mice (in vivo) Corcoran et al. 1985
Mice (in vivo) Hjelle et al. 1986
Mice (in vivo) Corcoran and Wong 1986
L-2-Oxothiazolidine-4-carboxylate Mice (in vivo) Hazelton et al. 1986
L-2-Methylthiazolidine-4-carboxylate
2-(Polyhydroxyalkyl)thiazolidine-4(R)- Mice (in vivo) Roberts et al. 1987
   carboxylic acids
Cystathionine Mice (in vivo) Kitamura et al. 1989
2-Methyl-thiazolidine-2,4-dicarboxylic acid HepG2 cells (in vitro) Wlodek and Rommelspacher 1997aMice (in vivo) Wlodek and Rommelspacher 1997b
Ribose cysteine Mice (in vivo) Roberts et al. 1992Mice (in vivo) Lucas et al. 2000
2(R,S)-n-Propylthiazolidine-4(R)-carboxylic acid Mice (in vivo) Srinivasan et al. 2001
N,S-bis-Acetyl-L-cysteine Mice (in vivo) Crankshaw et al. 2002
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(rate-limiting enzyme) is regulated by feedback
inhibition of GSH (Richman and Meister, 1975).
When GSH is consumed and the regulation of feed-
back inhibition is lost, the availability of cysteine as
a precursor can become the limiting factor for GSH
synthesis (Wang and Ballatori, 1998).
Various cysteine prodrugs have been reported
to protect the liver from APAP-induced hepatotox-
icity in experiments using animals or cultured cells
(Table 1).  The mechanism responsible for this pro-
tection may be metabolism of these prodrugs to L-
cysteine, which is incorporated into hepatic GSH
(Lauterburg et al., 1983; Corcoran and Wong, 1986;
Hazelton et al., 1986; Roberts et al., 1987).
Among these cysteine prodrugs, N-acetylcys-
teine (NAC) is the most widely used antidote for
APAP overdose in clinical practice.  Intravenous
administration of NAC to patients with APAP poi-
soning is effective for preventing APAP-induced
hepatotoxicity (Prescott, 1981; Smilkstein et al.,
1991).  Prescott (1981) reported that NAC given
intravenously 8 to 10 h after APAP ingestion was
Fig. 1.  Effect of SAMC or NAC treatment on APAP-
induced liver injury in male ddY mice.  APAP (500 mg/
kg) was orally administered to mice, and then SAMC
(100 mg/kg) or NAC (80 mg/kg) was given orally 1 h
after APAP administration.  The mice were anesthetized
with diethyl ether and blood samples were taken from
the right ventricle with a heparinized syringe 6 h after
APAP.  Plasma ALT activity was determined spectro-
photometrically with a commercially available kit.  The
data are expressed as means ± SE for 4 to 5 animals.
Plasma ALT activity in intact mice was 8 ± 1 IU/L (Note:
these values are too small to visualize).  *,** Significantly
different from the APAP + vehicle group (P < 0.05 and
0.01, respectively).  Unpublished data, Sumioka et al.
effective for preventing liver damage, hepatic fai-
lure, renal damage and death.  Oral administration
of NAC to patients with APAP poisoning was also
shown to be effective for preventing liver damage
(Rumack et al., 1981; Smilkstein et al., 1988).
Analysis of the national multicenter study (1976 to
1985) in the United States reported by Smilkstein et
al. (1988) demonstrated that oral treatment with
NAC was protective regardless of the initial plasma
APAP concentration when given within 8 h of
APAP ingestion.  They concluded that NAC treat-
ment should be started within 8 h of APAP inges-
tion, but that treatment is still indicated at least as
late as 24 h after ingestion.  As shown in Fig. 1, we
demonstrated that oral treatment of mice with NAC
1 h after APAP administration significantly sup-
pressed the increase in plasma ALT activity as an
index of liver injury.  The most appropriate route
and dose regimen of NAC for APAP-induced hepa-
totoxicity is still controversial.  However, retro-
spective and prospective studies suggest that NAC
treatment may be effective for fulminant liver fai-
lure after APAP overdose (Harrison et al., 1990;
Keays et al., 1991).
CYP2E1 inhibitors
The metabolism of APAP by CYP leads to the for-
mation of NAPQI as discussed in the “Reactive in-
termediate metabolite of APAP” section.  There-
fore, CYP inhibitors may be effective for APAP-
induced hepatotoxicity.  Of the CYP enzymes,
CYP2E1 plays the most important role in metabo-
lizing APAP.  Studies of CYP2E1 knockout mice
have revealed that CYP2E1 is the most important
factor in APAP biotransformation (Lee et al., 1996;
Zaher et al., 1998).
We have demonstrated that S-allylmercapto-
cysteine (SAMC), an organosulfur compound in
aged garlic extract, protects mice from APAP-
induced liver injury.  Oral treatment with SAMC
(100–200 mg/kg) suppressed the increase in plasma
ALT activity (Fig. 1) and the hepatic necrosis after
APAP overdose, and reduced APAP-induced mor-
tality.  The mechanism underlying this protection
involved the suppression of CYP2E1 activity
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Fig. 2.  Effect of CoQ10 or α-Toc pretreatment on
APAP-induced liver injury in male ICR mice.  CoQ10 (5
mg/kg), α-Toc (20 mg/kg) or vehicle was  intravenously
injected into mice 12 h before intraperitoneal adminis-
tration of APAP (400 mg/kg). The mice were anesthe-
tized with diethyl ether and blood samples were taken
from the right ventricle with a heparinized syringe 3 h
after APAP.  Plasma ALT activity was determined spec-
trophotometrically with a commercially available kit.
The data are expressed as means ± SE for at least 5 ani-
mals.  * Significantly different from the APAP + vehicle
group (P < 0.05).  From Amimoto et al., 1995 with some
modifications.
(Nakagawa et al., 1989; Sumioka et al., 1998, 2001).
Diallyl sulfide and phenethyl isothiocyanate, com-
pounds derived from garlic and cruciferous plants,
respectively, have also been shown to inhibit
CYP2E1 activity, and thereby to exhibit a protec-
tive effect against APAP-induced hepatotoxicity
(Hu et al., 1996; Li et al., 1997).  A synthetic com-
pound, 2-(allylthio)pyradine, inhibited CYP2E1
mRNA and protein expression, resulting in preven-
tion of APAP-induced liver damage (Kim et al.,
1997).  SAMC or diallyl sulfide treatment, not only
before but also after APAP overdose, can protect
animals from APAP-induced hepatotoxicity (Hu et
al., 1996; Sumioka et al., 2001), suggesting that
CYP2E1 inhibitor could serve as an antidote for
APAP overdose.
CYP2E1 is also known to be a key bioactiva-
tor of various carcinogens, such as azoxymethane
and N-nitrosodimethylamine (Yoo et al., 1990; Sohn
et al., 2001).  In this context, a CYP2E1 inhibitor
could be a potential inhibitor of carcinogenesis by
environmental carcinogens (Smith et al., 1995), and
its clinical application could be extended from
treatment of APAP-induced hepatotoxicity to treat-
ment of all CYP2E1-related disorders.
Antioxidants
Oxidative stress followed by lipid peroxidation is
also thought to contribute to the initiation or pro-
gression of APAP-induced hepatotoxicity (Wendel
et al., 1979; Albano et al., 1983, 1985), as described
in the “Oxidative stress” section.
We have demonstrated that intravenous pre-
treatment with the lipid-soluble antioxidants, CoQ10
(5 mg/kg) and α-Toc (20 mg/kg), can limit hepatic
injury produced by APAP overdose (Amimoto et al.,
1995).  CoQ10 is converted to CoQ10H2 in liver cells,
and thereafter acts as an antioxidant (Matsura et al.,
1992a, 1992b).  These lipid-soluble antioxidants
suppressed the increase in plasma ALT activity
(Fig. 2) and hepatic TBARS level without affecting
the hepatic GSH level.  L-Ascorbic acid and its esters
(Raghuram et al., 1978; Lake et al., 1981; Mitra et al.,
1991) and β-carotene (Baranowitz and Maderson,
1995) also exert protective action against APAP-
induced hepatotoxicity.  In addition, antioxidant en-
zymes such as superoxide dismutase and catalase
protect the liver from APAP-induced injury (Kyle
et al., 1987; Nakae et al., 1990).  Iron is well known
to play a major role in lipid peroxidation (Halliwell
and Gutteridge, 1990).  Sakaida et al. (1995) report-
ed that deferoxamine, an iron chelator, can protect
against APAP-induced hepatotoxicity.
Given that these antioxidants are effective
when administered before APAP, taking APAP
with them might be helpful for protecting against
toxicity by misadventure, especially as antioxidants
in nature, such as CoQ10, α-Toc, ascorbic acid and
β-carotene, have few side effects.
Heat shock protein (HSP) inducers
HSP is ubiquitous in nature, and expressed in both
prokaryotic and eukaryotic cells in response to a
variety of stresses (Hendrick and Hartl, 1993).  Ini-
tially, HSP was identified as a cellular response
protein to hyperthermia, but HSP induction has also
been observed after treatment of cells with a num-
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ber of chemical toxicants.  APAP-induced hepato-
toxicity has been shown to increase the expression
of HSP25 and HSP70i (Salminen et al., 1997a).  It is
generally accepted that the stimulus for increased
HSP synthesis in response to stresses is the pres-
ence of non-native proteins (Ananthan et al., 1986;
Goff and Goldberg, 1985).  In the case of APAP-
induced hepatotoxicity, covalent binding of NAPQI
to hepatic macromolecules is thought to play a
Fig. 3.  The metabolic pathways of APAP, and the mechanisms of, and protection against, APAP-induced hepatotox-
icity.  +, stimulation; –, inhibition.
pivotal role in triggering HSP induction (Salminen
et al., 1998).  HSP70i together with HSP25 may
function as a cytoprotective HSP to repair damaged
protein in the necrotic lesion.  The patterns of hepat-
ic HSP25 and HSP70i induction are clearly differ-
ent.  The level of HSP70i increases initially after
APAP overdose, and thereafter the level of HSP25
increases.  The induction time after APAP overdose
may differ with the severity of hepatotoxicity.  For
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example, at a lethal dose, HSP25 could be detected
24 h after APAP treatment (Sumioka et al., 2004),
whereas, at a necrotic but not lethal dose, it was de-
tectable 6 h after APAP treatment (Salminen et al.,
1997a).  Salminen et al. (1997b) reported that intra-
peritoneal pretreatment with amphetamine (15 mg/
kg) in mice causes an acute rise in core body tem-
perature to 40˚C for at least 1 h, increases the levels
of HSP25 and HSP70i, and protects the liver from
APAP-induced hepatotoxicity.  We have reported
that the level of expression of hepatic HSP25 may
be a crucial determinant of the fate of mice exposed
to APAP insult, because mortality following APAP
overdose declined rapidly after the appearance of
hepatic HSP25 (Sumioka et al., 2004).  These find-
ings suggest that HSP (HSP25 and 70i) inducer
might be a new type of antidote for APAP overdose.
Conclusion
APAP overdose causes hepatotoxicity, which is
sometimes fatal.  This hepatotoxicity is initiated by
the metabolic activation of APAP to NAPQI, a
reactive metabolite.  ROS generation and subse-
quent lipid peroxidation during APAP biotrans-
formation is likely to exacerbate APAP insult.
Even at  therapeutic doses, APAP hepatotoxicity
can occur when there are risk factors such as alco-
hol abuse, fasting and concomitant drug use.  NAC,
one of the cysteine prodrugs, has been traditionally
used to prevent the development of hepatotoxicity
following a significant overdose of APAP.  In addi-
tion to NAC, HSP inducers as well as CYP2E1 in-
hibitors and antioxidants may also be antidotes for
APAP overdose, on the basis of the mechanisms
underlying APAP toxicity (Fig. 3).
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